Success Metrics

Clinical Success Rate
88.2%

Based on 15 completed trials

Completion Rate
88%(15/17)
Active Trials
0(0%)
Results Posted
40%(6 trials)
Terminated
2(11%)

Phase Distribution

Ph phase_2
5
28%
Ph phase_1
2
11%
Ph phase_3
1
6%
Ph not_applicable
10
56%

Phase Distribution

2

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
2(11.1%)
Phase 2Efficacy & side effects
5(27.8%)
Phase 3Large-scale testing
1(5.6%)
N/ANon-phased studies
10(55.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

88.2%

15 of 17 finished

Non-Completion Rate

11.8%

2 ended early

Currently Active

0

trials recruiting

Total Trials

18

all time

Status Distribution
Active(1)
Completed(15)
Terminated(2)

Detailed Status

Completed15
Terminated2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
0
Success Rate
88.2%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (11.1%)
Phase 25 (27.8%)
Phase 31 (5.6%)
N/A10 (55.6%)

Trials by Status

enrolling_by_invitation16%
completed1583%
terminated211%

Recent Activity

0 active trials
Showing 5 of 18
enrolling_by_invitationphase_2

Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia

NCT03338387
completedphase_2

The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome

NCT00759291
completedphase_3

Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes

NCT01816165
completednot_applicable

Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes

NCT01580813
completednot_applicable

Lipolytic Effects of GH in Hypopituitary Patients in Vivo

NCT02782208
View all 18 trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT03338387Phase 2

Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia

Enrolling By Invitation
NCT00759291Phase 2

The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome

Completed
NCT01816165Phase 3

Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes

Completed
NCT01580813Not Applicable

Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes

Completed
NCT02782208Not Applicable

Lipolytic Effects of GH in Hypopituitary Patients in Vivo

Completed
NCT02792621Not Applicable

Increasing Mitochondrial Function on Skeletal Muscle Performance in Older Men

Completed
NCT03325491Not Applicable

Assessing the Effects of Increased Mitochondrial Function Exercise Training on Muscle Performance

Terminated
NCT00153179Phase 1

Free Fatty Acids and Vascular Function in Subjects With Diabetes

Completed
NCT02796950Not Applicable

The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion

Completed
NCT01209416Not Applicable

The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin

Completed
NCT01980524Phase 2

The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes

Completed
NCT01488409Phase 2

Effects of Acipimox on Mitochondrial Function in Obesity

Completed
NCT02256722Phase 1

In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects

Completed
NCT00246402Not Applicable

Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV

Completed
NCT00943059Not Applicable

Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function

Completed
NCT01260376Not Applicable

Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise

Completed
NCT00549614Not Applicable

Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure

Completed
NCT00449423Phase 2

Metabolic Modulation as Treatment in Acute Heart Failure

Terminated

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18